Available trials Leverage Partner with are often small collaborations to conduct a or between multinational Clinical underpowered, existing investigator-initiated Trials and national CKD clinical trial on (ISN- recruitment is trial networks common ACT), challenging to facilitate interventions such ASN multinational as bicarbonate, uric Kidney trials acid reduction, Health ACEi/ARB or Initiative, phosphate binder French therapies CKD clinical trials network and others Little is known Do more Create a toolbox of KDIGO* about how to studies of validated manage symptom instruments for symptoms of management common CKD G4+ CKD G4+, symptoms that can which is a key be used in trials or in treatment supporting studies objective for patients * Although KDIGO could act as a catalyst to establish these initiatives, they will likely require the creation of a dedicated organization or structure to ensure sustainability. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; ISN, International Society of Nephrology, ASN, American Society of Nephrology.
Available trials are often small or underpowered, and recruitment is challenging Leverage collaborations between existing national CKD trial networks to facilitate multinational trials Partner with to conduct a multinational investigator-initiated clinical trial on common interventions such as bicarbonate, uric acid reduction, ACEi/ARB or phosphate binder therapies Clinical Trials (ISN- ACT), ASN Kidney Health Initiative, French CKD clinical trials network and others Little is known about how to manage symptoms of CKD G4+, which is a key treatment objective for patients Do more studies of symptom management Create a toolbox of validated instruments for common CKD G4+ symptoms that can be used in trials or in supporting studies KDIGO* * Although KDIGO could act as a catalyst to establish these initiatives, they will likely require the creation of a dedicated organization or structure to ensure sustainability. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; ISN, International Society of Nephrology, ASN, American Society of Nephrology.
1-s2.0-S0085253818301364-mmc10.docx